Rotator Cuff Repairs With or Without BioEnthesis™ Augmentation
1 other identifier
interventional
100
1 country
5
Brief Summary
Rotator cuff (RC) injuries are particularly prevalent, difficult to repair, and attachment between the bone and tendon is notoriously difficult to achieve. The most common method and current standard of care (SOC) for reattaching connective tissues (e.g., ligaments, tendons) to bone typically involves suture anchor-based techniques, but this is fraught with problems. More specifically, re-tearing of the connective tissue after this procedure occurs in 30-60% of cases, and can be even higher in patients who engage in smoking, have a diagnosis of diabetes, etc. To address these clinical challenges, Sparta Biopharma Inc. (Sparta) developed a unique technology, called BioEnthesis, to improve the connection between the tendon and bone. Pre-clinical in vivo studies demonstrated that the biphasic bovine cancellous matrix regenerated at the bone-soft tissue interface-thereby leading to high structural integrity and will likely lead to reduced re-tear rates over time. The investigators hypothesize that patients in this interventional cohort will experience enhanced mobility, reduced pain, and less re-tears after RC procedures versus a standard suture anchor-based repair.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Jul 2023
Longer than P75 for phase_4
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 28, 2023
CompletedFirst Submitted
Initial submission to the registry
February 22, 2024
CompletedFirst Posted
Study publicly available on registry
March 4, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2027
July 13, 2026
July 1, 2026
4 years
February 22, 2024
July 10, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Rates of re-tear
Re-tear rates following rotator cuff repair using BioEnthesis versus standard of care. Assessed with (1) 12-month follow-up shoulder MRI and assigning Sugaya Classification, and (2) adverse events evaluation at each follow-up timepoint
Post-operation at 3-months, 6-months, and 12-months
Secondary Outcomes (13)
Change in the Visual Analogue Scale (VAS) from before surgery to after surgery
Pre-operation (baseline) and then post-operation at 3-months, 6-months, and 12-months
Change in the return to activities of daily living (ADL) from before surgery to after surgery
Pre-operation (baseline) and then post-operation at 3-months, 6-months, and 12-months
Change in the Concomitant medications (ConMeds) from before surgery to after surgery
Pre-operation (baseline) and then post-operation at 3-months, 6-months, and 12-months
Change in the Single Assessment Numeric Evaluation (SANE) from before surgery to after surgery
Pre-operation (baseline) and then post-operation at 6-months, and 12-months
Change in the American Shoulder and Elbow Surgeons Standardized Shoulder Form (ASES) from before surgery to after surgery
Pre-operation (baseline) and then post-operation at 6-months, and 12-months
- +8 more secondary outcomes
Study Arms (2)
BioEnthesis
EXPERIMENTALAllogenic, acellular, biphasic allograft (BioEnthesis)
Standard of Care
ACTIVE COMPARATORStandard rotator cuff repair (suture and anchor based technique)
Interventions
Rotator cuff repair using BioEnthesis allograft patch
Rotator cuff repair using standard of care sutures and anchors
Eligibility Criteria
You may qualify if:
- DEERS-eligible
- Adults, between the ages of 18-65 (inclusive)
- Presenting with a rotator cuff tear that is reparable surgically (a reparable tear is defined as tear of the RC where it is possible to bring the retracted tendon edge back to the greater tuberosity of the humerus under minimal tension)
- Ability to undergo surgery to repair rotator cuff tear
- Willingness to commit to study procedures including study intervention and a 12-month follow-up
- Fluency in speaking, reading, comprehending English
- tendon full thickness reparable RC tear (full thickness tear is defined as a tear that involves the majority of supraspinatus and less than half of the infraspinatus under minimal tension, with no subscapularis involvement beyond the upper border)
- Patients who have high-grade partial thickness tears where the surgeon elects to complete the tear during surgery before repairing the tendon(s)
You may not qualify if:
- Previous shoulder surgery (excluding acromioplasty or diagnostic arthroscopy)
- Inability to receive an MRI
- Current (within the past 6 months) tobacco user
- Unwilling to remain tobacco free for the duration of the study
- Current lower limb injuries requiring walking assist devices such as crutches and walkers
- Diagnosed with systemic arthritis
- Significant neck pathology
- Active joint or systemic infection
- Currently enrolled, or plans to enroll, in another clinical trial during this study (that would affect the patient's safety or results of this trial)
- Significant muscle paralysis of the shoulder girdle
- Currently pregnant or plans to become pregnant during this study
- Inability of the surgeon to repair the tear with remaining defect no greater than 10 mm in diameter
- Inability of the surgeon to repair the tear with less than 1cm of medialization
- Evidence of other significant shoulder pathology (such as Grade III osteoarthritis)
- Has a history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or drug abuse or addiction
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Brooke Army Medical Centerlead
- Sparta Biopharmacollaborator
Study Sites (5)
10th Medical Group - Air Force Academy
Air Force Academy, Colorado, 80840, United States
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889, United States
University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Duke University
Durham, North Carolina, 27710, United States
Brooke Army Medical Center
San Antonio, Texas, 78234, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jonathan Dickens, MD
Duke University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Orthopaedic Surgeon
Study Record Dates
First Submitted
February 22, 2024
First Posted
March 4, 2024
Study Start
July 28, 2023
Primary Completion (Estimated)
August 1, 2027
Study Completion (Estimated)
August 1, 2027
Last Updated
July 13, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share